Literature DB >> 22115967

Extracellular HSPA1A promotes the growth of hepatocarcinoma by augmenting tumor cell proliferation and apoptosis-resistance.

Feng-Hua Wu1, Ye Yuan, Dong Li, Sheng-Jun Liao, Bin Yan, Jing-Jing Wei, Yuan-Hong Zhou, Jian-Hua Zhu, Gui-Mei Zhang, Zuo-Hua Feng.   

Abstract

Intracellular HSP70 has been implicated as a cytoprotective protein, whereas the effect of extracellular HSP70 on tumor cells has not been fully understood to date. Here we report that extracellular HSPA1A, a stress-inducible member of HSP70 family, could promote tumor growth. HSPA1A promoted the proliferation of H22 hepatocarcinoma cells through TLR2 and TLR4 signaling. The effect of HSPA1A was abolished by inhibiting NF-κB. HSPA1A also augmented the apoptosis-resistance of H22 cells by activating NF-κB, thus to promote the proliferation of H22 cells in presence of mitomycin C. Furthermore, the promoting effect of HSPA1A on tumor cell proliferation was existent after the removal of HSPA1A, which might involve HSPA1A-promoted upregulation of TLR4 expression in tumor cells and release of HMGB1 from tumor cells. These findings suggest that extracellular HSPA1A functions as endogenous ligand for TLR2 and TLR4 to facilitate tumor growth.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22115967     DOI: 10.1016/j.canlet.2011.11.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

Review 1.  Extracellular heat shock proteins: a new location, a new function.

Authors:  Antonio De Maio; Daniel Vazquez
Journal:  Shock       Date:  2013-10       Impact factor: 3.454

2.  Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway.

Authors:  Yi Zhe; Yan Li; Dan Liu; Dong-Ming Su; Jin-Gang Liu; Hang-Yu Li
Journal:  Tumour Biol       Date:  2016-08-04

Review 3.  Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis?

Authors:  Jorge André Gomes Lopes; Marta Borges-Canha; Pedro Pimentel-Nunes
Journal:  World J Hepatol       Date:  2016-01-28

4.  Extracellular HSP70/HSP70-PCs promote epithelial-mesenchymal transition of hepatocarcinoma cells.

Authors:  Hangyu Li; Yan Li; Dan Liu; Hongzhi Sun; Dongming Su; Fuquan Yang; Jingang Liu
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

5.  Extracellular HSP70/HSP70-PCs regulate hepatocarcinoma cell migration and invasion via RhoA.

Authors:  Zhe Yi; Yan Li; Dan Liu; Jingang Liu; Hangyu Li
Journal:  Oncol Lett       Date:  2016-12-30       Impact factor: 2.967

6.  Toll-like receptor 4 and its associated proteins as prognostic factors for HCC treated by post-radiotherapy surgery.

Authors:  Zhi-Feng Wu; Ying Wang; Ping Yang; Jia-Zhou Hou; Jian-Ying Zhang; Yong Hu; Zhao-Chong Zeng
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

7.  Role of GATA3 exon 6 germline mutations in breast cancer progression in Egyptian female patients.

Authors:  Iman H Ibrahim; Heba G Abdel-Aziz; Fatema Em Hassan; Hesham Sa El-Sameea
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-17

Review 8.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

9.  The complex function of hsp70 in metastatic cancer.

Authors:  Kata Juhasz; Anna-Maria Lipp; Benedikt Nimmervoll; Alois Sonnleitner; Jan Hesse; Thomas Haselgruebler; Zsolt Balogi
Journal:  Cancers (Basel)       Date:  2013-12-20       Impact factor: 6.639

10.  Characterization and functional analysis of a slow-cycling subpopulation in colorectal cancer enriched by cell cycle inducer combined chemotherapy.

Authors:  Feng-Hua Wu; Lei Mu; Xiao-Lan Li; Yi-Bing Hu; Hui Liu; Lin-Tao Han; Jian-Ping Gong
Journal:  Oncotarget       Date:  2017-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.